Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Scott David Solomon, M.D.

Co-Author

This page shows the publications co-authored by Scott Solomon and Muthiah Vaduganathan.
Connection Strength

23.440
  1. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail. 2022 Jul 22.
    View in: PubMed
    Score: 0.986
  2. Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation. 2022 06 07; 145(23):1741-1743.
    View in: PubMed
    Score: 0.975
  3. Health Status Trajectories Before and After Hospitalization for Heart Failure. Circulation. 2022 06 21; 145(25):1872-1874.
    View in: PubMed
    Score: 0.975
  4. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
    View in: PubMed
    Score: 0.943
  5. Considering dose in pharmacological therapies for heart failure - Authors' reply. Lancet. 2021 01 23; 397(10271):275.
    View in: PubMed
    Score: 0.889
  6. Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. Eur J Heart Fail. 2020 09; 22(9):1525-1530.
    View in: PubMed
    Score: 0.865
  7. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J. 2020 07 01; 41(25):2356-2362.
    View in: PubMed
    Score: 0.855
  8. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 07 11; 396(10244):121-128.
    View in: PubMed
    Score: 0.848
  9. Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. Reply. N Engl J Med. 2020 06 11; 382(24):e92.
    View in: PubMed
    Score: 0.848
  10. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020 05 01; 5(5):576-581.
    View in: PubMed
    Score: 0.845
  11. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 04 23; 382(17):1653-1659.
    View in: PubMed
    Score: 0.840
  12. How Do SGLT-2 Inhibitors Work to Prevent Heart Failure? JACC Heart Fail. 2020 01; 8(1):67-69.
    View in: PubMed
    Score: 0.826
  13. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020 01 28; 75(3):245-254.
    View in: PubMed
    Score: 0.818
  14. Expanding the global borders of heart failure: the SHOP and PEOPLE studies. Eur Heart J. 2018 05 21; 39(20):1781-1783.
    View in: PubMed
    Score: 0.739
  15. Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. JACC Heart Fail. 2018 08; 6(8):653-661.
    View in: PubMed
    Score: 0.728
  16. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.
    View in: PubMed
    Score: 0.728
  17. Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial. Eur J Heart Fail. 2022 Jul 27.
    View in: PubMed
    Score: 0.247
  18. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
    View in: PubMed
    Score: 0.245
  19. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 03; 10(3):184-197.
    View in: PubMed
    Score: 0.240
  20. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail. 2022 05; 24(5):794-803.
    View in: PubMed
    Score: 0.239
  21. Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.
    View in: PubMed
    Score: 0.239
  22. Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. J Card Fail. 2022 06; 28(6):1035-1039.
    View in: PubMed
    Score: 0.239
  23. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Jan 05.
    View in: PubMed
    Score: 0.237
  24. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circ Heart Fail. 2021 12; 14(12):e008597.
    View in: PubMed
    Score: 0.235
  25. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2022 04; 28(4):554-563.
    View in: PubMed
    Score: 0.235
  26. Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots. JAMA. 2021 07 27; 326(4):311-313.
    View in: PubMed
    Score: 0.230
  27. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.229
  28. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.
    View in: PubMed
    Score: 0.228
  29. Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. J Gen Intern Med. 2021 08; 36(8):2532-2535.
    View in: PubMed
    Score: 0.228
  30. Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. Circulation. 2021 07 13; 144(2):177-179.
    View in: PubMed
    Score: 0.227
  31. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. J Am Coll Cardiol. 2021 07 27; 78(4):330-343.
    View in: PubMed
    Score: 0.227
  32. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2021 05; 9(5):374-382.
    View in: PubMed
    Score: 0.225
  33. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. Eur J Heart Fail. 2021 08; 23(8):1346-1356.
    View in: PubMed
    Score: 0.224
  34. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail. 2021 01; 9(1):65-73.
    View in: PubMed
    Score: 0.221
  35. Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. JAMA Cardiol. 2020 Nov 13.
    View in: PubMed
    Score: 0.219
  36. Neprilysin and Corin: It Takes Two to Tango. JACC Heart Fail. 2021 02; 9(2):96-99.
    View in: PubMed
    Score: 0.219
  37. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med. 2020 Sep 09.
    View in: PubMed
    Score: 0.217
  38. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 10; 8(10):844-855.
    View in: PubMed
    Score: 0.217
  39. Angioedema in COVID-19. Eur Heart J. 2020 09 07; 41(34):3283-3284.
    View in: PubMed
    Score: 0.217
  40. Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. JACC Heart Fail. 2020 08; 8(8):698-699.
    View in: PubMed
    Score: 0.215
  41. Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth. JACC Heart Fail. 2020 07; 8(7):597-598.
    View in: PubMed
    Score: 0.214
  42. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. JACC Heart Fail. 2020 08; 8(8):640-653.
    View in: PubMed
    Score: 0.213
  43. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jul 21; 76(3):280-288.
    View in: PubMed
    Score: 0.212
  44. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.
    View in: PubMed
    Score: 0.212
  45. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 05; 8(5):372-381.
    View in: PubMed
    Score: 0.210
  46. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol. 2020 04 14; 75(14):1644-1656.
    View in: PubMed
    Score: 0.209
  47. Reply: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 03; 8(3):245-246.
    View in: PubMed
    Score: 0.209
  48. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.205
  49. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.202
  50. Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. Eur J Heart Fail. 2019 10; 21(10):1288-1291.
    View in: PubMed
    Score: 0.200
  51. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 07; 12(7):e006125.
    View in: PubMed
    Score: 0.199
  52. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.195
  53. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018 10 01; 3(10):1000-1005.
    View in: PubMed
    Score: 0.189
  54. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. Eur J Heart Fail. 2018 04; 20(4):677-686.
    View in: PubMed
    Score: 0.178
  55. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J. 2022 07 14; 43(27):2573-2587.
    View in: PubMed
    Score: 0.062
  56. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25?000 Medicare beneficiaries. Eur J Heart Fail. 2022 Jun 11.
    View in: PubMed
    Score: 0.061
  57. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. JACC Heart Fail. 2022 08; 10(8):543-555.
    View in: PubMed
    Score: 0.061
  58. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation. 2022 Aug 09; 146(6):438-449.
    View in: PubMed
    Score: 0.061
  59. Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. Eur J Heart Fail. 2022 05; 24(5):861-866.
    View in: PubMed
    Score: 0.060
  60. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022 02 16; 8(2):165-178.
    View in: PubMed
    Score: 0.060
  61. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 02 08; 79(5):504-510.
    View in: PubMed
    Score: 0.060
  62. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 12 07; 10(23):e021494.
    View in: PubMed
    Score: 0.059
  63. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021 09; 107(17):1407-1416.
    View in: PubMed
    Score: 0.057
  64. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.
    View in: PubMed
    Score: 0.057
  65. Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. Am Heart J. 2021 07; 237:45-53.
    View in: PubMed
    Score: 0.056
  66. Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation. 2021 03 02; 143(9):949-958.
    View in: PubMed
    Score: 0.055
  67. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. JACC Heart Fail. 2021 01; 9(1):1-12.
    View in: PubMed
    Score: 0.055
  68. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 11 17; 76(20):2368-2378.
    View in: PubMed
    Score: 0.055
  69. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 10; 8(10):800-810.
    View in: PubMed
    Score: 0.054
  70. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. JACC Heart Fail. 2020 05; 8(5):347-358.
    View in: PubMed
    Score: 0.052
  71. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. Circ Heart Fail. 2020 01; 13(1):e006638.
    View in: PubMed
    Score: 0.052
  72. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Circulation. 2019 12 17; 140(25):2108-2118.
    View in: PubMed
    Score: 0.051
  73. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. JACC Heart Fail. 2019 12; 7(12):1022-1028.
    View in: PubMed
    Score: 0.051
  74. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.050
  75. Reply: Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI. J Am Coll Cardiol. 2019 07 09; 74(1):165-166.
    View in: PubMed
    Score: 0.050
  76. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. Eur J Heart Fail. 2018 12; 20(12):1760-1763.
    View in: PubMed
    Score: 0.048
  77. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
    View in: PubMed
    Score: 0.044
  78. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017 04; 19(4):552-562.
    View in: PubMed
    Score: 0.041
  79. Site selection for heart failure clinical trials in the USA. Heart Fail Rev. 2015 Jul; 20(4):375-83.
    View in: PubMed
    Score: 0.038
  80. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013 Dec 11; 2(6):e000536.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.